Understand the source comparison
Peptide Research News May 2026 Roundup: Key Comparison
Triple Receptor Agonist GLP-1/GIP/Glucagon 24.7% weight loss at 28 weeks (vs 20.9% tirzepatide baseline) Glucagon engagement drives thermogenesis without muscle catabolism Obesity + T2DM treatment ceiling raised significantly This is the metabolic peptide benc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Triple Receptor Agonist
- GLP-1/GIP/Glucagon
- 24.7% weight loss at 28 weeks (vs 20.9% tirzepatide baseline)
- Glucagon engagement drives thermogenesis without muscle catabolism
- Obesity + T2DM treatment ceiling raised significantly
- This is the metabolic peptide benchmark for 2026–2028. Dose titration protocols will need refinement, but efficacy is undeniable.
- CNS Delivery (Intranasal)
- Chitosan-Peptide Complex
- 18–22% CNS bioavailability vs <5% IV baseline
- Tight junction modulation via nasal mucosa
- Neuroprotective peptides bypass blood-brain barrier
- Delivery was the bottleneck. This solves it. Expect rapid clinical translation into neurodegenerative trials.
- CNS Delivery (Tat Conjugate)
- Cell-Penetrating Peptide-Cerebrolysin Analogue
- 14% BBB penetration via transcytosis
- Heparan sulfate binding triggers receptor-mediated transport
- Cognitive enhancement peptides become systemically viable
- More invasive than intranasal but compatible with subcutaneous injection. Broadens therapeutic accessibility.
- Thymic Immunomodulator
- Thymalin (RA Trial)
- 45% DAS28 reduction at 24 weeks
- T-cell reconstitution + Treg expansion
- Autoimmune disease treatment without broad immunosuppression
- First peptide to show clinically meaningful autoimmune effect without infection risk. Game-changing if Phase 3 replicates.